Omrix Biopharmaceuticals, Inc. Announces Third Quarter 2006 Financial Results Date And Conference Call

23 Oct 2006

·www.biospace.com

Financial StatementAntibody

NEW YORK--(BUSINESS WIRE)--OMRIX Biopharmaceuticals, Inc. (“OMRIX” or the “Company”)(NASDAQ: OMRI), a commercial-stage biopharmaceutical company that develops and markets biosurgical and antibody-based products, will announce financial results for the third quarter ended September 30, 2006 before the open of U.S. financial markets on Tuesday, November 7, 2006. An accompanying conference call to discuss the results will be held the same day at 10:00 a.m. ET; 7:00 a.m. PT.

Organizations

OMRIX Biopharmaceuticals, Inc.

Indications

Targets

Drugs

Chat with Hiro

Hot reports

GPRC5D Target Patent Research Report

Patsnap Synapse

Global Drug R&D Express (July 2024)

PatSnap Synapse

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Patsnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.